None of the other clinical-pathologic parameters assessed (including overall survival, disease-specific survival, and time to metastasis) significantly correlated with PD-L1 positivity (H-score) in tumor cells or with the relative density of CD3+, CD8+ or PD-1+ cells in tumor-associated lymphocytes (Table 2 and Supplementary Materials, Tables S1–S4). The gene discussed is CD8A; the disease is neoplasm.